EP Patent

EP4637727A1 — Nucleic acid-lipid particles

Assigned to Universiteit Utrecht Holding BV · Expires 2025-10-29 · 1y expired

What this patent protects

The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in p…

USPTO Abstract

The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in preventing and/or treating a disease, in particular for use in preventing and/or treating cancer. The present invention furthermore pertains to a method for producing a composition comprising said nucleic acid-lipids particles.

Drugs covered by this patent

Patent Metadata

Patent number
EP4637727A1
Jurisdiction
EP
Classification
—
Expires
2025-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Universiteit Utrecht Holding BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.